Chronic B-Cell Leukemia (CBCL) Overview

Save information for later
Sign Up

Learn About Chronic B-Cell Leukemia (CBCL)

View Main Condition: Leukemia

What is the definition of Chronic B-Cell Leukemia (CBCL)?
Chronic B cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic B cell leukemia, the bone marrow produces too many B lymphocytes, which are white blood cells that fight infection. Chronic B cell leukemia represents 95% of all chronic lymphocytic leukemias.
What are the symptoms of Chronic B-Cell Leukemia (CBCL)?
Individuals with early chronic B cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic B cell leukemia may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); night sweats; weight loss; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic B-Cell Leukemia (CBCL)?
Treatment for chronic B cell leukemia depends on the stage. Early stage chronic B cell leukemia may not need treatment and may involve watchful waiting. Treatment for intermediate and advanced stages chronic B cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic B-Cell Leukemia (CBCL) Local Doctors?
Dr. John C. Allen
Hematology Oncology | Hematology | Oncology
Dr. John C. Allen
Hematology Oncology | Hematology | Oncology

Baptist Memorial Hospital Union County, Inc.

504 Azalea Dr, Suite A, 
Oxford, MS 
 (2.0 mi)
662-636-4444
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Allen is a Hematologist Oncology specialist and a Hematologist in Oxford, Mississippi. Dr. Allen and is rated as an Advanced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, Angiosarcoma, and Familial Pancreatic Cancer. Dr. Allen is currently accepting new patients.

Dr. Milton D. Hobbs
Internal Medicine
Dr. Milton D. Hobbs
Internal Medicine
551 Azalea Dr, 
Oxford, MS 
 (2.2 mi)
662-234-0332
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Milton Hobbs is an Internal Medicine provider in Oxford, Mississippi. Dr. Hobbs and is rated as an Experienced provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Urethritis, Lung Cancer, Hypertension, and Glucocorticoid-Remediable Aldosteronism. Dr. Hobbs is currently accepting new patients in some locations.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Julian B. Hill
Hematology Oncology | Hematology
Dr. Julian B. Hill
Hematology Oncology | Hematology
961 South Gloster Street, 
Tupelo, MS 
 (46.5 mi)
662-844-9166
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julian Hill is a Hematologist Oncology specialist and a Hematologist in Tupelo, Mississippi. Dr. Hill and is rated as a Distinguished provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Inflammatory Breast Cancer, Gastroesophageal Junction Cancer, Paget Disease of the Breast, Lung Adenocarcinoma, and Bone Marrow Aspiration. Dr. Hill is currently accepting new patients.

View All Doctors
What are the latest Chronic B-Cell Leukemia (CBCL) Clinical Trials?
Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This correlative study aims to understand the pharmacodynamic effects and clonal dynamics in response to epcoritamab by obtaining and analyzing lymph node, bone marrow, and blood samples from subjects enrolled in GCT3013-03 trial sponsored by Genmab at NIH. Samples will be collected before and at multiple time points during treatment with epcoritamab. National Heart, Lung, and Blood Institute (NHL...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Who is this study for: Adult patients with Small Lymphocytic Lymphoma or Chronic Lymphocytic Leukemia
Enrollment Status: Recruiting
Publish Date: February 26, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2

Summary: This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the ...

View All Clinical Trials